In an era where business-critical information is exchanged instantly, unsecured communication channels are a significant risk.

Dr. Dina Radenkovic, CEO of Gameto, identifies strategies to close the gap in women's health and how we can better incentivize research and development in this area.

In the Phase III CALYPSO trial, eneboparatide demonstrated statistical significance in achieving albumin-adjusted serum calcium normalization while eliminating the need for active vitamin D and oral ...

The deals are expected to shorten manufacturing timelines for cell therapies and reduce administration times for oncology ...

Jonathon Whitton, AuD, PhD, VP, auditory global program head, Regeneron, discusses how the focus of technology development is shifting toward ensuring safety and continuous hearing for children.

The increasing costs and complexity of R&D in the pharmaceutical industry have necessitated the adoption of strategic ...

Data from the Phase III MINT trial found that Uplizna demonstrated a greater reduction in Myasthenia Gravis Activities of ...

Dr. Dina Radenkovic, CEO of Gameto, identifies the main contributors to the gap in in women's health innovation.

Jonathon Whitton, AuD, PhD, VP, auditory global program head, Regeneron, discusses how the focus of technology development is shifting toward ensuring safety and continuous hearing for children.

Deal to acquire Covis is expected to expand Azurity’s portfolio across multiple complex dosage forms and key therapeutics ...

New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and ...

A panel discussion at the Global Life Science Partnering and Investor Conference discusses various strategies and trends in ...